Physician profile
Roopitha Kaval
NPI 1407346026
$2,006.19
in general payments reported to CMS, 2019-2025
20 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $582 · 2023: $275 · 2024: $508 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.27 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $308.97 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $255.94 | 2022-2023 | Jardiance, Lyumjev |
| Dexcom, INC. | $241.01 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $201.95 | 2022-2023 | Rybelsus, Ozempic |
| Amgen INC. | $166.54 | 2023-2024 | Evenity |
| Sequel Med Tech, LLC | $153.92 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $118.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.13 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $81.57 | 2023 | Idacio |
| Horizon Therapeutics Plc | $74.72 | 2023 | Tepezza |
| Abbvie INC. | $67.00 | 2022-2025 | |
| Pfizer INC. | $54.75 | 2022-2023 | |
| Ascensia Diabetes Care US INC. | $43.52 | 2025 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $17.72 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.95 | 2021 | |
| Tandem Diabetes Care, INC. | $15.87 | 2021 | |
| Corcept Therapeutics | $14.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopitha Kaval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.